BMY logo

Bristol-Myers Squibb (BMY) Free cash flow

annual FCF:

$13.94B+$1.29B(+10.20%)
December 1, 2024

Summary

  • As of today (April 16, 2025), BMY annual free cash flow is $13.94 billion, with the most recent change of +$1.29 billion (+10.20%) on December 1, 2024.
  • During the last 3 years, BMY annual FCF has fallen by -$1.29 billion (-8.48%).
  • BMY annual FCF is now -8.48% below its all-time high of $15.23 billion, reached on December 31, 2021.

Performance

BMY Free cash flow Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherBMYcash flow metrics

quarterly FCF:

$4.06B-$1.21B(-22.90%)
December 1, 2024

Summary

  • As of today (April 16, 2025), BMY quarterly free cash flow is $4.06 billion, with the most recent change of -$1.21 billion (-22.90%) on December 1, 2024.
  • Over the past year, BMY quarterly FCF has increased by +$139.00 million (+3.54%).
  • BMY quarterly FCF is now -22.90% below its all-time high of $5.27 billion, reached on September 30, 2024.

Performance

BMY quarterly FCF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherBMYcash flow metrics

TTM FCF:

$13.94B+$139.00M(+1.01%)
December 1, 2024

Summary

  • As of today (April 16, 2025), BMY TTM free cash flow is $13.94 billion, with the most recent change of +$139.00 million (+1.01%) on December 1, 2024.
  • Over the past year, BMY TTM FCF has increased by +$1.29 billion (+10.20%).
  • BMY TTM FCF is now -8.48% below its all-time high of $15.23 billion, reached on December 31, 2021.

Performance

BMY TTM FCF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherBMYcash flow metrics

Free cash flow Formula

FCF = Cash From Operations − CAPEX

BMY Free cash flow Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+10.2%+3.5%+10.2%
3 y3 years-8.5%+3.5%+10.2%
5 y5 years+89.1%+3.5%+10.2%

BMY Free cash flow Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-8.5%+16.7%-22.9%+149.4%-7.9%+30.1%
5 y5-year-8.5%+89.1%-22.9%+149.4%-8.5%+40.3%
alltimeall time-8.5%+5982.7%-22.9%+413.1%-8.5%+5982.7%

Bristol-Myers Squibb Free cash flow History

DateAnnualQuarterlyTTM
Dec 2024
$13.94B(+10.2%)
$4.06B(-22.9%)
$13.94B(+1.0%)
Sep 2024
-
$5.27B(+155.2%)
$13.80B(+6.6%)
Jun 2024
-
$2.06B(-19.1%)
$12.95B(+3.5%)
Mar 2024
-
$2.55B(-35.0%)
$12.51B(-1.1%)
Dec 2023
$12.65B(+5.9%)
$3.92B(-11.0%)
$12.65B(+8.2%)
Sep 2023
-
$4.41B(+170.8%)
$11.69B(+9.0%)
Jun 2023
-
$1.63B(-39.5%)
$10.72B(-3.3%)
Mar 2023
-
$2.69B(-9.1%)
$11.08B(-7.3%)
Dec 2022
$11.95B(-21.6%)
$2.96B(-14.0%)
$11.95B(-6.1%)
Sep 2022
-
$3.44B(+73.0%)
$12.72B(-10.9%)
Jun 2022
-
$1.99B(-44.1%)
$14.28B(-5.7%)
Mar 2022
-
$3.56B(-4.8%)
$15.14B(-0.6%)
Dec 2021
$15.23B(+14.5%)
$3.74B(-25.2%)
$15.23B(+4.6%)
Sep 2021
-
$5.00B(+75.3%)
$14.57B(+24.7%)
Jun 2021
-
$2.85B(-21.9%)
$11.69B(-11.5%)
Mar 2021
-
$3.65B(+18.8%)
$13.20B(-0.8%)
Dec 2020
$13.30B(+80.3%)
$3.07B(+45.3%)
$13.30B(+9.4%)
Sep 2020
-
$2.11B(-51.5%)
$12.16B(-2.0%)
Jun 2020
-
$4.36B(+16.3%)
$12.41B(+24.9%)
Mar 2020
-
$3.75B(+94.4%)
$9.94B(+34.8%)
Dec 2019
$7.37B(+20.6%)
$1.93B(-18.4%)
$7.37B(-15.3%)
Sep 2019
-
$2.37B(+25.1%)
$8.71B(+17.7%)
Jun 2019
-
$1.89B(+59.5%)
$7.40B(+16.2%)
Mar 2019
-
$1.19B(-63.7%)
$6.37B(+4.1%)
Dec 2018
$6.12B(+44.9%)
$3.27B(+209.5%)
$6.12B(+64.7%)
Sep 2018
-
$1.05B(+22.8%)
$3.71B(-9.6%)
Jun 2018
-
$859.00M(-8.2%)
$4.11B(-10.4%)
Mar 2018
-
$936.00M(+8.5%)
$4.59B(+8.7%)
Dec 2017
$4.22B(+129.0%)
$863.00M(-40.5%)
$4.22B(-4.7%)
Sep 2017
-
$1.45B(+8.6%)
$4.43B(+9.6%)
Jun 2017
-
$1.34B(+134.4%)
$4.04B(+40.2%)
Mar 2017
-
$570.00M(-46.8%)
$2.88B(+56.4%)
Dec 2016
$1.84B(+43.4%)
$1.07B(+0.8%)
$1.84B(+34.5%)
Sep 2016
-
$1.06B(+497.2%)
$1.37B(+129.5%)
Jun 2016
-
$178.00M(-137.9%)
$597.00M(+83.7%)
Mar 2016
-
-$470.00M(-178.5%)
$325.00M(-74.7%)
Dec 2015
$1.28B(-51.0%)
$599.00M(+106.6%)
$1.28B(+20.4%)
Sep 2015
-
$290.00M(-408.5%)
$1.07B(-32.2%)
Jun 2015
-
-$94.00M(-119.2%)
$1.57B(-39.8%)
Mar 2015
-
$490.00M(+28.6%)
$2.61B(-0.3%)
Dec 2014
$2.62B(-12.8%)
$381.00M(-52.1%)
$2.62B(-24.0%)
Sep 2014
-
$796.00M(-15.9%)
$3.45B(-3.7%)
Jun 2014
-
$946.00M(+89.6%)
$3.58B(-11.5%)
Mar 2014
-
$499.00M(-58.8%)
$4.05B(+34.6%)
Dec 2013
$3.01B(-52.9%)
$1.21B(+30.2%)
$3.01B(+22.3%)
Sep 2013
-
$929.00M(-34.2%)
$2.46B(-58.9%)
Jun 2013
-
$1.41B(-360.0%)
$5.98B(+7.0%)
Mar 2013
-
-$543.00M(-182.1%)
$5.59B(-12.6%)
Dec 2012
$6.39B(+42.9%)
$661.00M(-85.1%)
$6.39B(-10.8%)
Sep 2012
-
$4.45B(+335.6%)
$7.17B(+65.4%)
Jun 2012
-
$1.02B(+286.7%)
$4.33B(+0.0%)
Mar 2012
-
$264.00M(-81.6%)
$4.33B(-3.2%)
Dec 2011
$4.47B(+10.0%)
$1.43B(-11.2%)
$4.47B(-0.8%)
Sep 2011
-
$1.61B(+58.4%)
$4.51B(+7.6%)
Jun 2011
-
$1.02B(+151.0%)
$4.19B(+1.2%)
Mar 2011
-
$406.00M(-72.4%)
$4.14B(+1.7%)
Dec 2010
$4.07B(+21.9%)
$1.47B(+13.6%)
$4.07B(+8.6%)
Sep 2010
-
$1.29B(+33.7%)
$3.75B(-0.3%)
Jun 2010
-
$968.00M(+189.0%)
$3.75B(+9.8%)
Mar 2010
-
$335.00M(-70.8%)
$3.42B(+2.5%)
Dec 2009
$3.33B(+20.6%)
$1.15B(-12.0%)
$3.33B(+47.0%)
Sep 2009
-
$1.30B(+106.3%)
$2.27B(+2.2%)
Jun 2009
-
$632.00M(+151.8%)
$2.22B(-10.9%)
Mar 2009
-
$251.00M(+209.9%)
$2.49B(-9.9%)
Dec 2008
$2.77B(+19.7%)
$81.00M(-93.6%)
$2.77B(-9.8%)
Sep 2008
-
$1.26B(+38.9%)
$3.06B(+32.1%)
Jun 2008
-
$904.00M(+72.2%)
$2.32B(+2.2%)
Mar 2008
-
$525.00M(+38.2%)
$2.27B(-1.6%)
Dec 2007
$2.31B
$380.00M(-25.8%)
$2.31B(+20.6%)
Sep 2007
-
$512.00M(-40.1%)
$1.92B(-10.8%)
DateAnnualQuarterlyTTM
Jun 2007
-
$855.00M(+51.9%)
$2.15B(+8.9%)
Mar 2007
-
$563.00M(-3853.3%)
$1.97B(+52.9%)
Dec 2006
$1.29B(+20.8%)
-$15.00M(-102.0%)
$1.29B(-7.8%)
Sep 2006
-
$744.00M(+9.4%)
$1.40B(+13.8%)
Jun 2006
-
$680.00M(-671.4%)
$1.23B(+254.2%)
Mar 2006
-
-$119.00M(-226.6%)
$347.00M(-67.5%)
Dec 2005
$1.07B(-54.9%)
$94.00M(-83.6%)
$1.07B(-26.5%)
Sep 2005
-
$574.00M(-384.2%)
$1.45B(+25.6%)
Jun 2005
-
-$202.00M(-133.6%)
$1.16B(-43.5%)
Mar 2005
-
$602.00M(+25.4%)
$2.05B(-13.4%)
Dec 2004
$2.37B(-6.1%)
$480.00M(+72.7%)
$2.37B(-15.7%)
Sep 2004
-
$278.00M(-59.8%)
$2.81B(-13.2%)
Jun 2004
-
$691.00M(-24.7%)
$3.23B(-7.4%)
Mar 2004
-
$918.00M(-0.4%)
$3.49B(+38.5%)
Dec 2003
$2.52B(-1164.1%)
$922.00M(+31.0%)
$2.52B(+38.6%)
Sep 2003
-
$704.00M(-25.8%)
$1.82B(+0.2%)
Jun 2003
-
$949.00M(-1890.6%)
$1.82B(+80.3%)
Mar 2003
-
-$53.00M(-124.1%)
$1.01B(-524.9%)
Dec 2002
-$237.00M(-105.4%)
$220.00M(-68.6%)
-$237.00M(-120.2%)
Sep 2002
-
$700.00M(+400.0%)
$1.17B(-6.2%)
Jun 2002
-
$140.00M(-110.8%)
$1.25B(-47.7%)
Mar 2002
-
-$1.30B(-179.6%)
$2.39B(-45.5%)
Dec 2001
$4.38B(+7.8%)
$1.63B(+109.8%)
$4.38B(+1.6%)
Sep 2001
-
$777.00M(-39.2%)
$4.31B(-5.9%)
Jun 2001
-
$1.28B(+84.1%)
$4.58B(+10.6%)
Mar 2001
-
$694.00M(-55.6%)
$4.14B(+1.9%)
Dec 2000
$4.06B(+15.6%)
$1.56B(+48.9%)
$4.06B(+7.0%)
Sep 2000
-
$1.05B(+25.3%)
$3.80B(+3.2%)
Jun 2000
-
$837.00M(+36.1%)
$3.68B(+4.2%)
Mar 2000
-
$615.00M(-52.5%)
$3.53B(+0.5%)
Dec 1999
$3.52B(+17.4%)
$1.30B(+39.1%)
$3.52B(+14.4%)
Sep 1999
-
$932.00M(+35.5%)
$3.07B(-6.5%)
Jun 1999
-
$688.00M(+14.9%)
$3.29B(+14.7%)
Mar 1999
-
$599.00M(-29.9%)
$2.87B(-4.2%)
Dec 1998
$2.99B(+75.2%)
$854.00M(-25.5%)
$2.99B(+24.5%)
Sep 1998
-
$1.15B(+329.6%)
$2.40B(+25.7%)
Jun 1998
-
$267.00M(-63.2%)
$1.91B(+2.4%)
Mar 1998
-
$726.00M(+175.0%)
$1.87B(+9.4%)
Dec 1997
$1.71B(-16.2%)
$264.00M(-59.8%)
$1.71B(-9.6%)
Sep 1997
-
$656.00M(+194.2%)
$1.89B(+2.8%)
Jun 1997
-
$223.00M(-60.6%)
$1.84B(-12.7%)
Mar 1997
-
$566.00M(+27.2%)
$2.11B(+3.2%)
Dec 1996
$2.04B(+2.7%)
$445.00M(-26.3%)
$2.04B(-0.8%)
Sep 1996
-
$604.00M(+23.0%)
$2.06B(-2.0%)
Jun 1996
-
$491.00M(-1.8%)
$2.10B(+15.0%)
Mar 1996
-
$500.00M(+8.5%)
$1.82B(-8.2%)
Dec 1995
$1.99B(+14.9%)
$461.00M(-28.5%)
$1.99B(-0.1%)
Sep 1995
-
$645.00M(+197.2%)
$1.99B(+18.0%)
Jun 1995
-
$217.00M(-67.3%)
$1.69B(-6.5%)
Mar 1995
-
$663.00M(+43.2%)
$1.80B(+4.3%)
Dec 1994
$1.73B(-14.0%)
$463.00M(+35.4%)
$1.73B(-4.8%)
Sep 1994
-
$342.00M(+2.4%)
$1.82B(-15.6%)
Jun 1994
-
$334.00M(-43.3%)
$2.15B(-6.1%)
Mar 1994
-
$589.00M(+6.9%)
$2.29B(+14.0%)
Dec 1993
$2.01B(+45.5%)
$551.00M(-18.7%)
$2.01B(+4.9%)
Sep 1993
-
$678.00M(+43.3%)
$1.92B(+8.6%)
Jun 1993
-
$473.00M(+53.6%)
$1.76B(+24.9%)
Mar 1993
-
$308.00M(-32.8%)
$1.41B(+2.3%)
Dec 1992
$1.38B(+14.4%)
$458.00M(-12.9%)
$1.38B(+2.1%)
Sep 1992
-
$526.00M(+334.7%)
$1.35B(+14.0%)
Jun 1992
-
$121.00M(-56.2%)
$1.19B(-2.6%)
Mar 1992
-
$276.00M(-35.7%)
$1.22B(+0.9%)
Dec 1991
$1.21B(-2.6%)
$429.00M(+19.2%)
$1.21B(+4.8%)
Sep 1991
-
$360.00M(+135.3%)
$1.15B(+2.3%)
Jun 1991
-
$153.00M(-42.3%)
$1.13B(-8.9%)
Mar 1991
-
$265.00M(-29.1%)
$1.24B(-0.2%)
Dec 1990
$1.24B(+95.1%)
$374.00M(+12.0%)
$1.24B(+43.2%)
Sep 1990
-
$334.00M(+27.0%)
$865.00M(+62.9%)
Jun 1990
-
$263.00M(-1.9%)
$531.00M(+98.1%)
Mar 1990
-
$268.00M
$268.00M
Dec 1989
$635.00M
-
-

FAQ

  • What is Bristol-Myers Squibb annual free cash flow?
  • What is the all time high annual FCF for Bristol-Myers Squibb?
  • What is Bristol-Myers Squibb annual FCF year-on-year change?
  • What is Bristol-Myers Squibb quarterly free cash flow?
  • What is the all time high quarterly FCF for Bristol-Myers Squibb?
  • What is Bristol-Myers Squibb quarterly FCF year-on-year change?
  • What is Bristol-Myers Squibb TTM free cash flow?
  • What is the all time high TTM FCF for Bristol-Myers Squibb?
  • What is Bristol-Myers Squibb TTM FCF year-on-year change?

What is Bristol-Myers Squibb annual free cash flow?

The current annual FCF of BMY is $13.94B

What is the all time high annual FCF for Bristol-Myers Squibb?

Bristol-Myers Squibb all-time high annual free cash flow is $15.23B

What is Bristol-Myers Squibb annual FCF year-on-year change?

Over the past year, BMY annual free cash flow has changed by +$1.29B (+10.20%)

What is Bristol-Myers Squibb quarterly free cash flow?

The current quarterly FCF of BMY is $4.06B

What is the all time high quarterly FCF for Bristol-Myers Squibb?

Bristol-Myers Squibb all-time high quarterly free cash flow is $5.27B

What is Bristol-Myers Squibb quarterly FCF year-on-year change?

Over the past year, BMY quarterly free cash flow has changed by +$139.00M (+3.54%)

What is Bristol-Myers Squibb TTM free cash flow?

The current TTM FCF of BMY is $13.94B

What is the all time high TTM FCF for Bristol-Myers Squibb?

Bristol-Myers Squibb all-time high TTM free cash flow is $15.23B

What is Bristol-Myers Squibb TTM FCF year-on-year change?

Over the past year, BMY TTM free cash flow has changed by +$1.29B (+10.20%)
On this page